Archive WILEX adhoc- and press releases 2011

ENGLISH DEUTSCH

Selected press releases and ad hocs of the former years can be found here.

2011
 2010 2009 2008 2007 2006 2005 2004 and before
14 December 2011 PR:WILEX and IBA report on follow up meeting with the FDA on further steps in the development of REDECTANE®
07 December 2011 PR:WILEX Inc. lists Oncogene Science® CA IX IHC Kit as an In-Vitro-Diagnostic with the FDA
21 November 2011 PR:WILEX AG: ARISER Independent Data Monitoring Committee (IDMC) recommends conducting the final analysis of the pivotal Phase III trial with RENCAREX®
AH:WILEX AG: ARISER Independent Data Monitoring Committee (IDMC) recommends conducting the final analysis of the pivotal Phase III trial with RENCAREX®
14 October 2011 AH:WILEX reports an adjustment of the goodwill of Heidelberg Pharma AG according to IFRS
13 October 2011 PR:WILEX publishes 9-month financial report 2011
10 October 2011 PR:WILEX Inc. and ALPCO Diagnostics sign marketing and distribution agreement for North America
05 October 2011 PR:FDA grants Fast Track designation to WILEX’s RENCAREX® for the adjuvant therapy of clear cell Renal Cell Carcinoma
15 September 2011 PR:WILEX starts first oral Phase I study with MEK inhibitor WX-554
03 August 2011 PR:WILEX’s subsidiary WILEX Inc. receives ISO certification
14 July 2011 PR:WILEX announces successful half year results
17 June 2011 PR:WILEX and IBA report on the Pre-BLA Meeting with the FDA and the next steps in the REDECTANE® approval process
AH:WILEX reports on the Pre-BLA Meeting with the FDA and the next steps in the REDECTANE® approval process
05 May 2011 PR:Patient recruitment in Phase II breast cancer trial with MESUPRON® successfully completed
02 May 2011 PR:WILEX grants exclusive US commercialisation rights for RENCAREX® to Prometheus
29 April 2011 AH:WILEX grants exclusive US commercialisation rights for RENCAREX® to Prometheus
13 April 2011 PR:WILEX reports on successful first half year 2010
22 February 2011 PR:WILEX reports on the successful financial year 2010
24 January 2011 PR:WILEX announces start of interim analysis for its Phase III ARISER registration trial with RENCAREX®
Print This Page Print This Page | Email This Page Email This Page    
Seite gelesen: 303 | Heute: 3